Biomedical Engineering Reference
In-Depth Information
Danzon PM, Wang RY, Wang L (2005) The impact of price regulation on the launch delay of new
drugs: evidence from twenty-five major markets in the 1990s. Health Econ 14(3):269-292
de Bekker-Grob EW, Hofman R, Donkers B, van Ballegooijen M, Helmerhorst TJM, Raat H,
Korfage IJ (2010a) Girls' preferences for HPV vaccination: a discrete choice experiment.
Vaccine 28(41):6692-6697
de Bekker-Grob EW, Hol L, Donkers B, van Dam L, Habbema JDF, van Leerdam ME, Kuipers EJ,
Essink-Bot ML, Steyerberg EW (2010b) Labeled versus unlabeled discrete choice experiments
in health economics: an application to colorectal cancer screening. Value Health 13(2):315-323
Dekimpe MG, Parker PM, Sarvary M (1998) Staged estimation of international diffusion models:
an application to global cellular telephone adoption. Technol Forecast Soc Change 57:105-132
Dekimpe MG, Parker PM, Sarvary M (2000) Global diffusion of technological innovations: a
coupled hazard approach. J Mark Res 37(February):47-59
Desiraju R, Nair H, Chintagunta P (2004) Diffusion of new pharmaceutical drugs in developing
and developed nations. Int J Res Mark 21(4):341-357, Special issue on Global Marketing
DiMasi JA (2000) Price trends for prescription: pharmaceuticals: 1995-1999. Background report
prepared for the US Department of Health and Human Services' conference on pharmaceutical
pricing practices, utilization and costs, Washington, DC, 8-9 Aug 2000. Available at
http://
aspe.hhs.gov/health/reports/Drug-papers/dimassi/dimasi-inal.htm
. Accessed 15 July 2011
DiMasi JA, Paquette C (2004) The economics of follow-on drug research and development: trends
in entry rates and the timing of development. Pharmacoeconomics 22(Suppl 2):1-14
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug
development costs. J Health Econ 22(2):151-185
Ding M, Eliashberg J (2008) A dynamic competitive forecasting model incorporating dyadic deci-
sion making. Manag Sci 54(4):820-834
Dodson JA Jr, Muller E (1978) Models of new product diffusion through advertising and word-of-
mouth. Manag Sci 24(15):1568-1578
Dolan RJ (1990) Conjoint analysis: a manager's guide case 9-590-059. Harvard Business School
Publishing, Boston
Donohue J, Berndt E (2004) Effects of direct-to-consumer advertising on medication choice: the
case of antidepressants. J Public Policy Mark 23:115-127
Dukes MNG, Haaijer-Ruskamp FM, de Jonckheere CP, Rietveld AH (2003) Drugs and money:
prices, affordability and cost containment. IOS Press, Amsterdam
Ekelund M, Persson B (2003) Pharmaceutical pricing in a regulated market. Rev Econ Stat
85(2):298-306
Eliashberg J, Jeuland AP (1986) The impact of competitive entry in a developing market upon
dynamic pricing strategies. Mark Sci 5(1):20-36
Emanuel EJ, Emanuel LL (1992) Four models of the physician-patient relationship. JAMA
267:2221-2226
Epstein RM, Alper BS, Quill TE (2004) Communicating evidence for participatory decision mak-
ing. JAMA 291:2359-2366
Fischer M, Albers S (2010) Patient- or physician-oriented marketing: what drives primary demand
for prescription drugs? J Mark Res 47:103-121
Frank RG, Salkever DS (1997) Generic entry and the pricing of pharmaceuticals. J Econ Manag
Strategy 6(1):75-90
Gatignon H, Robertson TS (1989) Technology diffusion: an empirical test of competitive effects.
J Mark 53(1):35-49
Givon M, Mahajan V, Muller E (1995) Software piracy: estimation of lost sales and the impact on
software diffusion. J Mark 59(1):29-37
Goldenberg J, Libai B, Muller E (2002) Riding the saddle: how cross-market communications can
create a major slump in sales. J Mark 66(2):1-16
Golder PN, Tellis GJ (1997) Will it ever fly? Modeling the takeoff of really new consumer dura-
bles. Mark Sci 16(3):256-270
Gonul FF, Carter F, Petrova E, Srinivasan K (2001) Promotion of prescription drugs and its impact
on physicians' choice behavior. J Mark 65:79-90
Search WWH ::
Custom Search